BRKR BRUKER CORP
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1109354 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.2%
TTM net income YoY-490.4%
TTM EPS YoY-587.5%
Revenue 3-yr CAGR7.6%
Net income 3-yr CAGR—
Margins
Gross margin47.7%
Operating margin-2.0%
Net margin-3.5%
FCF margin7.0%
EBITDA margin4.5%
Returns
ROE-5.2%
ROA-2.0%
ROIC (approx.)-1.4%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets59.8%
Debt / equity0.74x
Current ratio1.84x
Interest coverage-1.23x
Cash quality & payout
Operating cash flow / net income-2.77x
Accruals ratio-7.6%
Payout ratio—
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $874.00M | $838.50M | $823.40M | $977.20M | $860.50M | $797.40M | $801.40M | $979.60M |
| Cost of revenue | $444.70M | $422.50M | $443.60M | $528.00M | $481.10M | $439.50M | $410.20M | $486.30M |
| Gross profit | $429.30M | $416.00M | $379.80M | $449.20M | $379.40M | $357.90M | $391.20M | $493.30M |
| R&D expense | $92.00M | $94.30M | $101.30M | $99.60M | $98.30M | $100.20M | $97.10M | $104.40M |
| SG&A expense | $226.50M | $238.90M | $242.10M | $247.20M | $242.50M | $231.40M | $225.40M | $247.30M |
| Operating income | -$91.00M | -$65.30M | $10.20M | $76.30M | -$51.80M | $11.90M | $31.80M | $72.10M |
| Interest expense | $15.40M | $17.80M | $12.20M | $11.20M | $20.30M | $15.70M | $13.10M | $15.60M |
| Pretax income | -$120.30M | -$40.70M | $21.90M | $68.20M | -$71.80M | $500,000 | $25.10M | $56.10M |
| Income tax | -$12.20M | $14.20M | $2.50M | $37.80M | -$14.10M | -$3.10M | $8.70M | $40.70M |
| Net income | -$111.80M | -$52.00M | $14.40M | $26.00M | -$59.60M | $7.60M | $17.40M | $13.70M |
| EBITDA | -$36.90M | -$7.30M | $68.50M | $134.40M | $3.90M | $68.00M | $82.20M | $125.00M |
| EPS (basic) | -0.81 | -0.41 | 0.02 | — | -0.41 | 0.05 | 0.11 | — |
| EPS (diluted) | -0.81 | -0.41 | 0.02 | — | -0.41 | 0.05 | 0.11 | — |
| Dividends declared per share | — | — | — | — | 0.05 | 0.05 | 0.05 | 0.05 |
| Weighted avg. shares (diluted) | 152.50M | 152.30M | 152.70M | — | 151.80M | 151.70M | 151.90M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $119.70M | $184.90M | $133.40M | $298.80M | $297.30M | $96.20M | $187.70M | $186.70M |
| Receivables | $563.90M | $545.90M | $542.70M | $544.90M | $550.90M | $522.60M | $537.80M | $565.50M |
| Inventory | $1.10B | $1.12B | $1.12B | $1.09B | $1.20B | $1.22B | $1.12B | $1.07B |
| Current assets | $2.16B | $2.23B | $2.10B | $2.21B | $2.35B | $2.16B | $2.11B | $2.05B |
| PP&E, net | $695.70M | $714.10M | $719.60M | $744.80M | $746.70M | $758.50M | $689.00M | $669.30M |
| Goodwill | $1.29B | $1.43B | $1.57B | $1.55B | $1.55B | $1.65B | $1.53B | $1.51B |
| Intangibles | $859.20M | $867.80M | $902.40M | $899.60M | $918.90M | $969.60M | $901.70M | $912.50M |
| Total assets | $5.83B | $6.05B | $6.13B | $6.24B | $6.43B | $6.34B | $5.93B | $5.81B |
| Current liabilities | $1.17B | $1.20B | $1.36B | $1.28B | $1.27B | $1.35B | $1.34B | $1.28B |
| Short-term debt | $10.40M | $10.10M | $8.40M | $16.60M | $24.30M | $55.70M | $37.70M | $32.50M |
| Long-term debt | $1.70B | $1.81B | $1.66B | $1.85B | $1.98B | $2.38B | $2.08B | $2.06B |
| Total debt | $1.71B | $1.82B | $1.67B | $1.87B | $2.01B | $2.44B | $2.11B | $2.09B |
| Total liabilities | $3.49B | $3.62B | $3.63B | $3.73B | $3.94B | $4.47B | $4.08B | $3.99B |
| Shareholders' equity | $2.31B | $2.40B | $2.47B | $2.46B | $2.43B | $1.82B | $1.83B | $1.78B |
| Net debt | $1.59B | $1.64B | $1.54B | $1.57B | $1.71B | $2.34B | $1.93B | $1.91B |
| Shares outstanding | 152.72M | 152.35M | 152.22M | 152.14M | 151.39M | 151.72M | 151.52M | 151.68M |
| Cash flow statement | ||||||||
| Operating cash flow | $118.20M | -$77.40M | $71.20M | $229.80M | -$33.20M | -$127.50M | $65.00M | $190.00M |
| Capital expenditure | $21.50M | $28.80M | $24.20M | $22.60M | $20.90M | $21.30M | $26.00M | $36.70M |
| Free cash flow | $96.70M | -$106.20M | $47.00M | $207.20M | -$54.10M | -$148.80M | $39.00M | $153.30M |
| Investing cash flow | -$72.70M | -$25.30M | -$39.70M | -$55.50M | -$23.80M | -$91.10M | -$26.10M | -$60.60M |
| Financing cash flow | -$110.10M | $149.20M | -$204.90M | -$167.60M | $258.40M | $95.50M | -$51.20M | -$75.00M |
| Depreciation & amortization | $54.10M | $58.00M | $58.30M | $58.10M | $55.70M | $56.10M | $50.40M | $52.90M |
| Stock-based compensation | $6.10M | $5.60M | $6.00M | $2.80M | $6.00M | $5.70M | $5.60M | $9.70M |
| Dividends paid | $7.70M | $7.50M | $7.60M | $7.50M | $0 | $7.60M | $7.70M | $7.60M |
| Share buybacks | — | — | $0 | $0 | $0 | $0 | $10.00M | $0 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.